Cargando…
Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience
BACKGROUND: The recognition of idiopathic membranous nephropathy (IMN) as an autoimmune disease has paved the way for the use of B-cell-depleting agents, such as Rituximab (RTX), which is now a first-line drug for treating IMN with proven safety and efficacy. Nevertheless, the usage of RTX for the t...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Baishideng Publishing Group Inc
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923863/ https://www.ncbi.nlm.nih.gov/pubmed/36793628 http://dx.doi.org/10.12998/wjcc.v11.i3.566 |